Options traders are pricing lower future volatility for BlackRock’s iShares Bitcoin Trust (IBIT) compared to its recent actual price swings. The implied volatility is 37.4%, below the realized volatility of 45.5% over the past month, suggesting traders anticipate calmer market conditions ahead. This comes as about $15 billion in Bitcoin options are set to expire on Sept. 25, a key event that could influence price movements. Bitcoin currently trades near $84,751, with resistance around $87,000 and support near $76,000-$77,000.
The IBIT options market's implied volatility signals smaller price swings after Bitcoin's recent rebound. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Sep 25, 2026 18:22 WIB: Of 50 major cryptocurrencies priced on Pluang, 46 rose and 3 fell today. Notable movers include SNX at Rp4.632 with a 12.05% increase and a typical hold time of 69 days, BAL at Rp16.297 up 11.14%, and ALGO at Rp2.109 rising 10.71% with 82% sell order activity.
Assured Guaranty Ltd. (NYSE: AGO) saw its stock price pressured to a new 52-week low of $68.04 despite a recent upgrade to "Buy" by Roth Capital. The company is involved in the financial restructuring of Brightline Florida, where a subsidiary insured...
Legacy Education Inc. reported Q4 2026 earnings with an EPS of $0.13, missing analyst estimates of $0.15, and revenue of $20.1 million, slightly below expectations. Despite this, the company achieved a 12% year-over-year revenue increase in Q4 and a ...
Carnival Corporation & plc is set to report Q3 earnings with analysts forecasting $8.39 billion in revenue and $1.36 EPS, reflecting a 4.9% decline from last year. The company's stock has dropped 27% recently due to a 30% surge in Brent oil prices, w...
Oklo, a pre-revenue nuclear tech company, is developing advanced small modular reactors (SMRs) called Aurora Powerhouses aimed at clean energy for data centers. UBS set a price target of $41, indicating a 7.08% upside from the current $38.29 stock pr...
AbbVie and Johnson & Johnson are both strong dividend stocks trading near their 52-week highs, but they differ significantly in risk and growth. AbbVie shows faster revenue growth and a higher dividend yield, driven by its immunology drugs, but faces...
